GenoMed Names Prof. Werner Dubitzky, Leader in Systems Biology, to Science Advisory Board
ST. LOUIS, MO. – November 16, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a Next Generation DM™ (Disease Management) company that uses its expertise in genomics to improve clinical outcomes, announced today that it has named Professor Werner Dubitzky to its Science Advisory Board, a European leader in the new field of Systems Biology.
Werner Dubitzky received his BSc degree in electrical and communication engineering from the Augsburg University of Applied Science, Germany, in 1991 and his Ph.D. in artificial intelligence and machine learning from the University of Ulster, Northern Ireland, UK, in 1997. From January 2000 to December 2001 he spearheaded the data mining developments at the Intelligent Bioinformatics Systems Group at the German Cancer Research Center, Heidelberg, Germany. Since January 2002 he has held the Chair of Bioinformatics at the School of Biomedical Sciences, Faculty of Life and Health Science, at the University of Ulster at Coleraine, Northern Ireland, UK. He is Head of the Bioinformatics Research Group at the same institute. His current research interests include bioinformatics, systems biology, data and text mining, data warehousing, and grid technology.
Dr. David Moskowitz, GenoMed's CEO, said, "I am delighted that Professor Dubitzky, who is an international leader in Systems Biology, has agreed to help us organize the cancer-causing genes we hope to soon have into pathways. Knowing disease pathways will let us plan the best place to ambush the disease, and which targets to make drugs against."
Professor Dubitzky said, "I welcome the opportunity to apply our cutting edge machine protocols to a complex biological problem like uncovering the genetic pathways of common cancers. Although our work so far has been in mining gene expression data, our algorithms should lend themselves well to GenoMed's extensive SNP data."
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is a Next Generation DM(TM) (Disease Management) company whose mission is to improve clinical outcomes by identifying the genetic pathways that cause disease. GenoMed is currently marketing its protocol for delaying complications like kidney failure due to high blood pressure and diabetes. Eighty million Americans are at increased risk for kidney failure. GenoMed is also marketing its method for delaying emphysema, which 3 million Americans have, and another 60 million smokers are at increased risk of getting.
This fall and winter GenoMed is coordinating a nation-wide influenza trial using the Company's patent-pending protocol, which exploits already existing, FDA-approved drugs. Anyone can enroll simply by clicking on the "Flu trial" link at genomed.com.
. |
